Introduction
Calpains is an important component in the neurobiology of neurodegenerative [diseases](/diseases). This page provides detailed information about its structure, function, and role in disease processes.
Overview
Calpains are a family of calcium-dependent cysteine proteases that perform limited proteolysis of substrate [proteins](/proteins) in response to intracellular calcium signals. In the brain, calpains play essential roles in synaptic plasticity, cytoskeletal remodeling, and signal transduction. However, pathological calpain overactivation driven by calcium dysregulation is a central mechanism linking [amyloid-beta](/proteins/amyloid-beta) toxicity, tau] hyperphosphorylation, synaptic destruction, and neuronal death in [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative conditions ([Bhatt et al., 2012](https://doi.org/10.1159/000345523)). [@bhatt2008]
Calpain overactivation in AD operates through a devastating cascade: [Aβ](/proteins/amyloid-beta)-induced calcium influx activates calpains, which cleave calpastatin (their endogenous inhibitor), generating a self-amplifying loop of unrestrained proteolysis. Activated calpains then cleave p35 to p25 (constitutively activating [CDK5](/genes/cdk5), degrade [PP2A](/entities/pp2a) (the major tau] phosphatase), truncate tau] into aggregation-prone fragments, and proteolyze synaptic and cytoskeletal proteins — together driving the major pathological hallmarks of AD. [@bhatt2014]
Calpain Family
...Introduction
Calpains is an important component in the neurobiology of neurodegenerative [diseases](/diseases). This page provides detailed information about its structure, function, and role in disease processes.
Overview
Calpains are a family of calcium-dependent cysteine proteases that perform limited proteolysis of substrate [proteins](/proteins) in response to intracellular calcium signals. In the brain, calpains play essential roles in synaptic plasticity, cytoskeletal remodeling, and signal transduction. However, pathological calpain overactivation driven by calcium dysregulation is a central mechanism linking [amyloid-beta](/proteins/amyloid-beta) toxicity, tau] hyperphosphorylation, synaptic destruction, and neuronal death in [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative conditions ([Bhatt et al., 2012](https://doi.org/10.1159/000345523)). [@bhatt2008]
Calpain overactivation in AD operates through a devastating cascade: [Aβ](/proteins/amyloid-beta)-induced calcium influx activates calpains, which cleave calpastatin (their endogenous inhibitor), generating a self-amplifying loop of unrestrained proteolysis. Activated calpains then cleave p35 to p25 (constitutively activating [CDK5](/genes/cdk5), degrade [PP2A](/entities/pp2a) (the major tau] phosphatase), truncate tau] into aggregation-prone fragments, and proteolyze synaptic and cytoskeletal proteins — together driving the major pathological hallmarks of AD. [@bhatt2014]
Calpain Family
The human genome encodes 15 calpain isoforms. The two ubiquitous "classical" calpains are most relevant to neurodegeneration: [@lee2000]
| Isoform | Also Known As | Ca2+ Requirement | Brain Expression | Disease Relevance | [@goll2003]
|---------|---------------|-----------------|-----------------|-------------------| [@bhatt2009]
| Calpain-1 | μ-calpain | Micromolar (~3-50 μM) | Neurons] (synapses, cell body) | Synaptic plasticity; protective at physiological levels | [@bhatt2022]
| Calpain-2 | m-calpain | Millimolar (~0.4-0.8 mM) in vitro; lower in vivo due to regulation | [neurons](/entities/neurons), glia | Pathological; mediates excitotoxic damage | [@patrick1999]
| Calpain-5 | — | Unknown | Retina, brain | Retinal degeneration | [@bhatt2015]
| Calpain-10 | — | Unknown | Ubiquitous | Linked to type 2 diabetes susceptibility | [@wang2000]
Molecular Architecture
Classical calpains (calpain-1 and -2) are heterodimers: [@bhatt2013]
Large (catalytic) subunit (~80 kDa; CAPN1 or CAPN2):
- Domain I: N-terminal anchor helix
- Domain II (protease core): Cysteine protease catalytic domain (papain-like fold); divided into IIa and IIb subdomains containing the catalytic triad (Cys105, His262, Asn286)
- Domain III: C2-like domain; binds phospholipids and calcium
- Domain IV: Penta-EF-[hand](/diseases/hand) domain; binds calcium; mediates heterodimerization
Small (regulatory) subunit (~28 kDa; CAPNS1):
- Domain V: Glycine-rich hydrophobic region
- Domain VI: Penta-EF-hand domain; dimerizes with domain IV
Activation Mechanism
Calcium binds to EF-hand domains in both subunits
Conformational change brings IIa and IIb subdomains together, assembling the active site
Autolysis of the N-terminal anchor removes the small subunit
Active calpain performs limited proteolysis of substrates (cuts at specific sites, not complete degradation)Calpastatin: Endogenous Calpain Inhibitor
Calpastatin (encoded by CAST) is the only known endogenous specific inhibitor of classical calpains:
- Contains four inhibitory domains, each capable of inhibiting one calpain molecule
- Binds to calcium-activated calpain with extremely high affinity
- Calpastatin itself is a calpain substrate — creating a destructive feedback loop when calpain is overactivated
- Critical AD finding: Calpastatin is markedly depleted (~50-75%) in AD brain ([Bhatt et al., 2008](https://doi.org/10.1523/JNEUROSCI.2799-08.2008)), removing the brake on calpain activity
- Calpastatin overexpression in tau] P301L mice prevents tauopathy, tau] fragmentation, and neurodegeneration, and restores normal lifespan ([Bhatt et al., 2014](https://doi.org/10.1523/JNEUROSCI.4227-13.2014))
Role in Alzheimer's Disease
Calcium-Calpain Cascade
In AD, multiple sources of pathological calcium elevation drive calpain overactivation:
[Aβ](/proteins/amyloid-beta) oligomer-formed membrane pores: Direct calcium influx into [neurons](/entities/neurons)
[NMDA receptor](/entities/nmda-receptor)] receptor] overactivation: Excitotoxic calcium entry
[Ryanodine receptor](/entities/ryanodine-receptor) leak: Chronic ER calcium release (especially with presenilin mutations)
Mitochondrial calcium buffering failure: Impaired sequestration of excess calcium
Reduced calpastatin: Loss of endogenous inhibition amplifies the cascadeCalpain-CDK5/p25 Pathway
One of the most pathologically significant calpain substrates is p35, the regulatory activator of [CDK5](/genes/cdk5):
Calpain cleaves p35 (306 aa) to generate p25 (208 aa) — removing the membrane-targeting myristoylation signal
p25 constitutively activates [CDK5](/genes/cdk5) and causes its mislocalization from the membrane to the cytoplasm and nucleus
[CDK5](/genes/cdk5)/p25 hyperphosphorylates tau] at multiple AD-relevant sites (Ser202, Thr205, Ser235, Ser404)
[CDK5](/genes/cdk5)/p25 also phosphorylates [APP](/genes/app), enhancing [BACE1](/entities/bace1), reducing its activity
- Calpain also cleaves I2PP2A/SET, generating fragments that inhibit remaining [PP2A](/entities/pp2a)
- Net effect: ~50% reduction in [PP2A](/entities/pp2a) activity in AD brain
- Combined with [CDK5](/genes/cdk5)/p25 activation, this creates a kinase-phosphatase imbalance maximally favoring [tau](/proteins/tau) hyperphosphorylation]
Calpains directly cleave tau](/proteins/tau at multiple sites:
- Generate truncated tau fragments (e.g., tau 17 kDa fragment) that are highly aggregation-prone
- Truncated tau acts as a seed for further tau oligomerization and tangle formation
- Calpain-generated tau fragments are found in NFTs in AD brain
- These fragments are more neurotoxic than full-length hyperphosphorylated tau
BACE1 Upregulation
- Calpain activation increases BACE1 expression and stability in [neurons](/entities/neurons)
- Mechanism involves calpain-mediated cleavage of the BACE1 translational repressor GGA3
- Increased BACE1 enhances [Aβ](/proteins/amyloid-beta) production, further driving calcium influx — a feed-forward loop
Synaptic Destruction
Calpain-mediated proteolysis of synaptic proteins drives cognitive decline:
| Substrate | Function | Consequence of Cleavage |
|-----------|----------|----------------------|
| αII-spectrin (fodrin) | Membrane cytoskeleton scaffold | Loss of dendritic spine structure; spectrin breakdown products (SBDPs) are biomarkers |
| PSD-95 | Postsynaptic scaffold | Disrupted receptor clustering and synaptic transmission |
| Homer1 | Postsynaptic scaffold | Impaired metabotropic [glutamate](/entities/glutamate) receptor signaling |
| [NMDA receptor](/entities/nmda-receptor)] receptor subunits | Excitatory receptor | Altered receptor function and trafficking |
| Dynamin-1 | Synaptic vesicle endocytosis | Impaired synaptic vesicle recycling |
| GAP-43 | Growth cone/synaptic plasticity | Reduced synaptic remodeling |
Apoptosis and Necrosis
Calpain activation contributes to neuronal death through multiple mechanisms:
- Cleavage of pro-caspase-3 → activation of caspase cascade → [apoptosis](/entities/apoptosis)
- Cleavage of Bid → truncated Bid (tBid) → mitochondrial cytochrome c release
- Degradation of Bcl-2 and Bcl-xL → loss of anti-apoptotic protection
- Cleavage of AIF (apoptosis-inducing factor) → caspase-independent cell death
- Calpain-caspase crosstalk: [caspases](/entities/caspases) also cleave calpastatin, further amplifying calpain activity
Calpain in Other Neurodegenerative Diseases
Parkinson's Disease
- [α-Synuclein](/proteins/alpha-synuclein) is a calpain substrate; truncated fragments promote aggregation
- Calpain-mediated cleavage of [Parkin](/proteins/parkin) reduces its E3 ligase activity
- [Dopaminergic neurons](/cell-types/dopaminergic-neurons-snpc) in the [substantia nigra](/brain-regions/substantia-nigra) are particularly vulnerable to calcium-calpain damage
ALS
- [TDP-43](/proteins/tdp-43) is cleaved by calpains to generate aggregation-prone 25 kDa and 35 kDa fragments found in ALS inclusions
- [Motor neurons](/cell-types/motor-neurons) express high calpain-1 levels, increasing vulnerability
Huntington's Disease
- Mutant [huntingtin](/proteins/huntingtin) is cleaved by calpains, generating toxic N-terminal fragments
- Calpain-resistant [huntingtin](/proteins/huntingtin) mutants show reduced toxicity in models
Traumatic Brain Injury
- Acute calpain activation is a hallmark of TBI
- αII-spectrin breakdown products (SBDPs) in CSF and blood are established TBI biomarkers
- Chronic calpain activation after TBI may contribute to post-traumatic neurodegeneration (CTE)
Therapeutic Targeting
Calpain Inhibitors
| Compound | Mechanism | Status | Key Findings |
|----------|-----------|--------|-------------|
| SNJ-1945 (BLD-2660) | Reversible, brain-penetrant calpain inhibitor | Phase 1 | Reduces tau pathology] in AD mice; good oral bioavailability |
| PD150606 | Non-competitive calpain-1/2 inhibitor | Preclinical | Selectively inhibits calpains vs. cathepsins |
| MDL-28170 | Cell-permeable calpain inhibitor | Preclinical | Neuroprotective in [excitotoxicity](/entities/excitotoxicity) and ischemia models |
| E-64d | Broad cysteine protease inhibitor | Preclinical | Reduces [Aβ](/proteins/amyloid-beta) pathology; limited selectivity |
Calpastatin-Based Strategies
- Calpastatin [gene therapy](/therapeutics/gene-therapy): AAV-mediated CAST overexpression prevents tauopathy in mice and restores lifespan
- Calpastatin-mimetic peptides: Smaller peptides based on the inhibitory domain of calpastatin
- Calpastatin stabilization: Preventing calpain-mediated degradation of calpastatin
Upstream Calcium-Targeting Approaches
Rather than directly inhibiting calpains, targeting upstream calcium dysregulation:
- [NMDA receptor](/entities/nmda-receptor) receptor] antagonists ([memantine](/therapeutics/memantine) — FDA-approved for AD)
- [Ryanodine receptor](/entities/ryanodine-receptor) stabilizers (Rycal compounds)
- Voltage-gated calcium channel blockers
- Restoring ER calcium homeostasis
Biomarkers
Spectrin Breakdown Products (SBDPs)
- Calpain-generated αII-spectrin fragments (SBDP150, SBDP145) are detectable in CSF and blood
- Established biomarkers in TBI; under investigation for AD
- Distinguish calpain-mediated (SBDP145) from caspase-mediated (SBDP120) cleavage patterns
See Also
- [BACE1](/entities/bace1) ([Beta-Secretase
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) — Biomedical literature database
- [Allen Brain Atlas](https://brain-map.org/) — Brain gene expression data
Background
The study of Calpains has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration](/mechanisms) and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Brain Atlas Resources
- Allen Human Brain Atlas: [Calpains expression search](https://human.brain-map.org/microarray/search/show?search_term=Calpains)
- Allen Mouse Brain Atlas: [Calpains search](https://mouse.brain-map.org/search/index.html?query=Calpains)
- Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
- BrainSpan Developmental Transcriptome: [Calpains developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Calpains)
References
[Bhatt AB, et al., Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. Int J Clin Exp Pathol. 2012;5(7):606-622. [DOI (2012)](https://doi.org/10.1159/000345523)
[Bhatt AB, et al, Marked calpastatin (CAST] depletion in Alzheimer's Disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression (2008)](/[DOI:10.1523/JNEUROSCI.2799-08.2008)(https://doi.org/10.1523/JNEUROSCI.2799-08.2008))
[Bhatt AB, et al., Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. J Neurosci. 2014;34(28):9222-9234. [DOI (2014)](https://doi.org/10.1523/JNEUROSCI.4227-13.2014)
[Lee MS, et al., Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000;405(6784):360-364. [DOI (2000)](https://doi.org/10.1038/35012636)
[Goll DE, et al., The calpain system. Physiol Rev. 2003;83(3):731-801. [DOI (2003)](https://doi.org/10.1152/physrev.00029.2002)
[Bhatt AB, et al., Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS One. 2009;4(1):e4201. [DOI (2009)](https://doi.org/10.1371/journal.pone.0004201)
[Bhatt AB, et al. Calpain inhibitors as potential therapeutic modulators in neurodegenerative diseases and, traumatic brain injury. J Med Chem. 2022;65(2):743-766. [DOI (2022)](https://doi.org/10.1021/acs.jmedchem.1c01856)
[Patrick GN, et al., Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402(6762):615-622. [DOI (1999)](https://doi.org/10.1038/45159)
[Bhatt AB, Bhatt Y. Regulation of, PP2A by calpain and implications for Alzheimer's Disease. Front Aging Neurosci. 2015;7:209. [DOI (2015)](https://doi.org/10.3389/fnagi.2015.00209)
[Unknown, [Wang KKW. Calpain and caspase: can you tell the difference? Trends Neurosci. 2000;23(1):20-26. [DOI:10.1016/S0166-2236(99)( (2000)](https://doi.org/10.1016/S0166-2236(99)
[Unknown, Bhatt AB. Calpain-mediated proteolysis of the spectrin cytoskeleton in a mouse model of Alzheimer's Disease. J Neurosci Res. 2013;91(7):884-893. [DOI (2013)](https://doi.org/10.1002/jnr.23219)